Bibliographic Details
| Title: |
Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications. |
| Authors: |
Wang, Kean, Chen, Feiyang, Wang, Jiang, Liu, Hong |
| Source: |
Acta Pharmaceutica Sinica B; Jan2025, Vol. 15 Issue 1, p35-51, 17p |
| Subject Terms: |
THYROID hormone receptors, DRUG discovery, CLINICAL indications, NUCLEAR proteins, PROTEIN receptors |
| Abstract: |
Thyroid hormone receptors (THRs), a crucial nuclear receptor protein family, primarily consist of two categories: α receptors and β receptors. Among them, THR β is the primary subtype of thyroid hormone that confers benefits to the liver. In the last two decades, there have been efforts to develop THR β agonists that selectively yield beneficial effects on the liver, such as lowering triglycerides and cholesterol, while reducing adverse effects on the heart, muscle, and bone. This paper systematically reviews strategies to enhance the safety of THR β agonists for the treatment of MASH, with a focus on improving the selectivity of THR α and increasing the distribution of the drug in the liver. Additionally, we explore the potential application of this target in addressing other medical indications. This is a comprehensive review of recent progress of THR β agonists on drug structure optimization and disease indications. [Display omitted] [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Pharmaceutica Sinica B is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Supplemental Index |
